Latice, do you have your head around the Cinven angle? I'm looking at the fundamentals here on the deal with Cinven.
Cinven calls it its most "lucrative" deal. And it really seems here that people are ignoring Cinven is a leading private equity firm in Europe. As RAD10 mentioned, a reverse take over might be in the works and that means shareholders get the boot. Nicely or not? Well, it all depends on management and it's pretty clear to me, at least, that someone has some BIG BOOTS! LOL ;-) I got the "boot" on a PE attempt on a oil gamble and I couldn't sit down for at day. Anyone ever tried standing up while sleeping?? ;-) LOL
I know you've read all the regulatory fillings on this and sleep on a bed made up of all the paper (can't be comfy can it? ;-) so I'm hoping you can shed some light on this. Someone I know brought it up but only had questions, no answers.
Cinven packaged AMCo after jacking up drug price and just before the deal with Concordia? Now that deal has earnout that is due this month but which can be deferred to Feb at 8% interest calculated daily. But only half of it can be put off.
The "deal" also states a bunch of vague things that gives some of us the feeling that AMCo isn't fully within the Concordia space even though the sale was apparently "completed Oct 21 2015:".
"On October 21, 2015, Cinven completed its sale of Amdipharm Mercury Limited (AMCo) to Concordia Healthcare Corp., (Concordia) for an enterprise value of US$3.5 billion, through a combination of cash, common shares of Concordia, and a maximum performance-based earnout of US$220 million over the next 12 months, from October 1, 2015."
You know how much of a COMPLETE CYNIC I am right? So tell me fellow bear, do you have the details of the "customary" stuff stated in the NR?
"Cinven has entered into a governance agreement with
Concordia, whereby it has agreed to customary lock-up, standstill and transfer restrictions."
https://concordiarx.com/concordia-healthcare-completes-amco-acquisition/